Maturation and migration to lymph nodes (LNs) constitutes a central paradigm in conventional dendritic cell (cDC) biology but remains poorly defined in humans. Using our organ donor tissue resource, we analyzed cDC subset distribution, maturation, and migration in mucosal tissues (lungs, intestines), associated lymph nodes (LNs), and other lymphoid sites from 78 individuals ranging from less than 1 year to 93 years of age. The distribution of cDC1 (CD141 hi CD13 hi ) and cDC2 (Sirp-a + CD1c + ) subsets was a function of tissue site and was conserved between donors. We identified cDC2 as the major mature (HLA-DR hi ) subset in LNs with the highest frequency in lung-draining LNs. Mature cDC2 in mucosal-draining LNs expressed tissue-specific markers derived from the paired mucosal site, reflecting their tissue-migratory origin. These distribution and maturation patterns were largely maintained throughout life, with site-specific variations. Our findings provide evidence for localized DC tissue surveillance and reveal a lifelong division of labor between DC subsets, with cDC2 functioning as guardians of the mucosa.
In Brief
Dendritic cells (DCs) function as tissue sentinels, but this role is difficult to study in humans. In this issue of Immunity, Granot et al. show through analysis of lymphoid and mucosal tissues that human DC maturation is tissue specific, associated with migration phenotypes, and predominantly observed among the cDC2 subset.
SUMMARY
Maturation and migration to lymph nodes (LNs) constitutes a central paradigm in conventional dendritic cell (cDC) biology but remains poorly defined in humans. Using our organ donor tissue resource, we analyzed cDC subset distribution, maturation, and migration in mucosal tissues (lungs, intestines), associated lymph nodes (LNs), and other lymphoid sites from 78 individuals ranging from less than 1 year to 93 years of age. The distribution of cDC1 (CD141 hi CD13 hi ) and cDC2 (Sirp-a + CD1c + ) subsets was a function of tissue site and was conserved between donors. We identified cDC2 as the major mature (HLA-DR hi ) subset in LNs with the highest frequency in lung-draining LNs. Mature cDC2 in mucosal-draining LNs expressed tissue-specific markers derived from the paired mucosal site, reflecting their tissue-migratory origin. These distribution and maturation patterns were largely maintained throughout life, with site-specific variations. Our findings provide evidence for localized DC tissue surveillance and reveal a lifelong division of labor between DC subsets, with cDC2 functioning as guardians of the mucosa.
INTRODUCTION
The context in which antigens are presented to T cells is critical for the initiation of adaptive immune responses to diverse antigens, including pathogens, tumors, autoantigens, and allergens. At the heart of this process lay dendritic cells (DCs), which can be subdivided into interferon-producing plasmacytoid (pDC), monocyte-derived (moDC), and classical or conventional (cDC), the latter which most efficiently promote naive T cell activation (for reviews, see Merad et al. [2013] and Steinman [2012] ). In mice, cDCs have been classified into two major subsets (Guilliams et al., 2014) : cDC1, which express CD8a or CD103 and specialize in cross-presentation to CD8 + T cells critical for immunity against intracellular pathogens, viruses, and cancer (Allan et al., 2003; Hildner et al., 2008; Pooley et al., 2001; Sung et al., 2006) ; and cDC2, which express CD11b and promote CD4 + T cell differentiation into subsets specializing in anti-viral, -fungal, or -helminth immunity (Plantinga et al., 2013; Schlitzer et al., 2013) . Due to the central role of cDCs in T cell activation, they have been implicated in the development of T-cell-mediated autoimmune, inflammatory, and allergic diseases (Steinman and Banchereau, 2007) . DC-based therapies to modulate T cell activation have proven efficacious in mouse models of cancer, autoimmunity, and transplantation; however, adapting these therapies to the treatment of human disease
has not yet fulfilled its promise (Palucka and Banchereau, 2012) . In contrast to mice, human DC research has by necessity focused on moDCs generated ex vivo from cultures of peripheral blood CD14 + monocytes with specific cytokines (Sallusto and Lanzavecchia, 1994) . The extent to which moDCs resemble primary cDCs responsible for T cell activation in tissues is not clear (Osugi et al., 2002; Segura et al., 2013) . Human CD141 + and CD1c + cDCs were originally identified in blood (Dzionek et al., 2000) and have been ontogenetically aligned to mouse cDC1 and cDC2, respectively (Bachem et al., 2010; Crozat et al., 2010; Jongbloed et al., 2010; Poulin et al., 2010) . Human DC subsets have been characterized in tissues (Guilliams et al., 2016; Haniffa et al., 2012; Heidkamp et al., 2016; Watchmaker et al., 2014) ; however, tissues were derived from isolated surgical explants from a small number of individuals at different life stages. The ability to adapt DC therapies to the diverse human population requires a comprehensive analysis of DC populations in multiple tissues at different life stages. A key paradigm in cDC biology is their capacity to acquire antigens in peripheral tissues, deliver them to draining lymph nodes (LNs), and undergo maturation through upregulation of major histocompatibility (MHC) and co-stimulatory molecules required for T cell activation (Banchereau and Steinman, 1998; Worbs et al., 2016) . Peripheral tissue cDC1s and cDC2s in mice both display a capacity to mature and migrate to the draining LNs during homeostasis or inflammation (Hammer and Ma, 2013) . Human tissue-migratory cDCs have been described based on phenotype or ex vivo migration assays in LN samples and skin (Haniffa et al., 2012; Segura et al., 2012) ; however, little is known about human cDC migration and maturation between peripheral tissues and their draining LNs due to the difficulty of obtaining these complementary sites for research. Thus, the defining characteristic of human cDCs as tissue sentinels remains poorly understood.
We have established a unique human tissue resource through collaborations with the local organ procurement agency, LiveOnNY, to obtain physiologically healthy lymphoid and mucosal tissues from human organ donors (Sathaliyawala et al., 2013; Thome et al., 2016a; Thome et al., 2014) . Our ability to obtain multiple tissues sites from individual donors of all ages has revealed insights into the compartmentalization of T cells, their homeostatic maintenance over life, and genesis and function in tissues during early life (Thome et al., 2016a; Thome et al., 2014) . Here, we asked whether tissue compartmentalization of immune responses was controlled at the level of tissue surveillance by DC. We developed a robust phenotyping scheme combining well-established (CD1c, CD141) and tissue-optimized (CD13, CD64) markers to distinguish cDC subsets in 14 diverse tissues sites, including lung, intestines, mucosal-draining and peripheral LNs, spleen, and gut-associated lymphoid tissues (GALT). Our analysis reveals new insights into human DC biology: that cDC subset composition is largely a function of the tissue site; that LNs differ in the extent of DC maturation, with lung-draining LNs having the highest proportion of mature DC compare to other LN sites; and that the cDC2 subset exhibits predominant maturation phenotypes within LNs compared to cDC1. This localization of DC maturation is largely maintained throughout life, with site-specific variation in subset distribution in early life and an overall increase in maturation throughout many sites in later life. Our findings provide new insights into the dynamic processes underlying adaptive immunity through tissue-specific DC maturation.
RESULTS

Analysis of DC Subsets in Multiple Human Tissues
We obtained multiple lymphoid and mucosal tissues from research-consented human organ donors as previously described (Sathaliyawala et al., 2013; Thome et al., 2016a; Thome et al., 2014) for a unique assessment of DC distribution, maturation, and migration properties in human tissues. For this study, tissues were acquired from 78 donors of diverse race and ethnicity across ten decades of human life ( Figure 1A and Table  S1 ). Tissue sites analyzed included blood, bone marrow (BM), secondary lymphoid organs (spleen and multiple LNs), mucosal sites (lung, jejunum, ileum, and colon), and GALT (Peyer's patches and appendix).
To identify and characterize cDC subsets, we combined flow cytometry and fluorescence imaging. For phenotypic characterization of DC subsets, we initially gated on live (DAPI low) singlet CD45 + , CD11c + HLA-DR + , CD14-, and lineage-negative and either CD141 + or CD1c + cells (Figure 1B), delineating cDC1 and cDC2, respectively. CD13 was reported to exhibit biased expression by cDC1-like cells in mice (Ghosh et al., 2012) , and we found it highly expressed on CD141 + , but not on CD1c + cells ( Figure 1B) , and expressed at intermediate levels on CD14 + cells (Figures S1A and S1B) . Coordinate expression of CD13 with CD141 and CD1c provided a clear segregation of cDC1, which also express Clec9A (Huysamen et al., 2008) and CD26, from cDC2, which were Sirp-a + (Watchmaker et al., 2014) ( Figures  1C-1E ). Several tissues contained a population of doublepositive CD141 + CD1c + cells ( Figure 1B ) also seen previously (Haniffa et al., 2012) , and we show that these cells express markers associated with cDC2 ( Figure 1C ). The monocyte and macrophage marker CD64 (Tamoutounour et al., 2012) Figure 2A) . Overall, the frequency of each subset was a function of the tissue site with minimal variation between donors for cDC1, cDC2, and CD14 + monocytes, with broader variation in pDC frequencies between donors ( Figure 2A ). For cDC1, overall frequencies ranged from < 0.01%-0.1% of CD45 + cells, with the highest relative frequencies in the spleen and LNs and lower frequencies in mucosal sites, blood, and bone marrow (Figure 2A , top). The overall frequencies of cDC2 were significantly higher than cDC1, ranging from < 0.1%-1% CD45 + cells, with higher frequencies of cDC2 in lung and jejunum compared to other mucosal sites and greater variation between LNs compared to cDC1 ( Figure 2A , second row). The frequency of pDC (gating strategy shown in Figure S1D ) ranged from 0.001%-0.1% of CD45 + cells and was highest in LNs, lungs, BM, and spleen and lower in the intestines (Figure 2A , third row). Finally, CD14 + cells ( Figure S1A ) exhibited the highest overall frequencies of all four subsets, ranging from < 1%-10% CD45 + cells, with highest frequencies in blood-rich tissues such as lungs and BM. These results provide a frequency distribution map of the key DC and monocyte populations throughout the human body and reveal subset-specific patterns, with cDC1 evenly distributed between spleen and multiple LNs and cDC2 varying in frequency between different lymphoid sites. To gain insights into associations between different subsets within and between tissue sites, we generated a composite circular diagram ( Figure 2B ) of the 14 tissues organized into blood-rich (blood, BM, spleen, and lungs), secondary lymphoid (spleen, LNs, and GALT), and mucosal (intestines and lungs) tissues. Within each tissue, pie charts depict cDC:pDC:monocyte (dark blue, orange, and green, respectively) and cDC1:cDC2 (red and light blue, respectively) ratios. Among the four populations analyzed, CD14 + cells dominated all tissues, particularly in blood-rich sites, while cDC2 was the predominant cDC subset in all sites. Although cDC1 and pDCs are low-frequency populations, their frequencies were higher in lymphoid compared to mucosal sites ( Figure 2B ). To dissect associations between cDC subsets in each tissue, we plotted cDC1 frequency versus cDC2:cDC1 ratio, resulting in segregation of the 14 tissues into five distinct groupings ( Figure 2C ): (1) circulatory, with low cDC1 frequencies and high cDC2:cDC1 ratios; (2) lymphoid tissues, with cDC2:cDC1 ratios averaging 2:1 subdivided into peripheral LNs with higher cDC1 frequencies, and (3) gutassociated lymphoid tissue (GALT) with lower cDC1 frequencies; (4) mucosal tissues with intermediate cDC1 frequencies and cDC2:cDC1 ratios; and (5) lung and lung LNs (LLNs), displaying higher cDC1 frequencies and high cDC2:cDC1 ratios. This analysis highlights the distinct cDC subset composition between mucosal and lymphoid sites and also between lymphoid sites draining different tissues that is conserved between diverse individuals.
Regional and Subset-Specific Differences in cDC Maturation in LNs
We sought to determine if the differences in cDC subset distribution between lymphoid sites corresponded to alterations in DC maturation. Studies in mice and humans have shown that MHC class II expression increases during DC maturation (Banchereau and Steinman, 1998) . In human tissues, we found that HLA-DR expression by cDC1 was at the low or intermediate levels in all tissues, with slightly higher levels found in the intestines (Figure 3A) . In contrast, HLA-DR expression by cDC2 varied between tissues, with the highest levels found in the LLN and tracheal LNs (TLNs) and elevated levels in pancreatic (P)LN and mesenteric (M)LN compared to iliac (I)LN and mucosal sites ( Figure 3A) . We further investigated the proportion of immature (MHCII lo ) and mature (MHCII hi ) DC subsets in different LNs, as done with mouse cDCs (Vermaelen et al., 2001) , to obtain a ''maturation ratio'' (mature:immature cDCs) for each site. LN mature cDCs also upregulate key co-stimulatory markers such as CD40, necessary for effective T cell activation, and possess higher side scatter, reflecting an increase in cellular complexity (Figures S2A and S2B) . As shown in a representative donor (Figure 3B) and in compiled data from 52 donors ( Figure 3C ), human spleens contain largely immature cDCs (low maturation ratio), while LNs have distinct proportions of immature and mature DCs, with TLN and LLN having the highest maturation ratio, followed by MLN, with ILN having the lowest maturation ratio.
Together, these results demonstrate that human cDC2s display tissue-specific maturation, with lung-draining LNs exhibiting higher cDC maturation than other mucosal and peripheral draining LNs.
We considered whether the increased frequency of mature cDC2 in the LLN compared to other LNs was due to intubation Secondary lymphoid tissues are shaded in purple, and mucosal tissues are shaded in tan; bloodrich sites are highlighted in gray. Tissue abbreviations are designated in Figure 1E , and Bld = blood; Spl = spleen; Lng = lung; Jej = jejunum; Ile = ileum; Col = colon; PP = Peyers Patches; App = appendix. S3 ) and when quantified in LNs from multiple donors, with some expected heterogeneity ( Figure 4B ). These results are consistent with our flow cytometry data, showing higher frequency and maturation of cDC2 in the LLN compared to other LNs (Figures 2 and 3 ).
LN Mature cDCs Display Migratory Characteristics
A key question regarding LN mature cDCs is whether these cells originate from tissue-maturing cDCs that migrate to the LNs through afferent lymphatics or mature directly in the LNs. In mice, mature LN cDCs were shown to be tissue derived in several models (Trautwein-Weidner et al., 2015; Vermaelen et al., 2001 ) and to require CCR7 expression for migration (Ohl et al., 2004) . Here, we examined coordinate expression of HLA-DR and CCR7 as markers of maturation and migration, respectively, on cDCs in human mucosal tissues paired with their draining LNs from the same individual. In the lung tissue of two representative donors ( Figure 5A , left panels), the majority of cDC1s and cDC2s exhibited an immature (HLA-DR lo CCR7 lo ) phenotype; however, there were significant fractions of HLA-DR hi CCR7 + cells among the cDC2 subset, with much lower frequencies of this phenotype observed on the cDC1 subset. Analysis of the complementary LLNs from these same individuals ( Figure 5A , right panels) reveals higher frequencies of HLA-DR hi CCR7 + cDCs in the LLN compared to the lung and among the cDC2 compared to the cDC1 subset in the LLN. Indeed, we found that the overall hierarchy of increased cDC2 maturation in the lung correlated with cDC2 maturation in the LLN, with cDC2 maturation levels in the LLN always higher than in the lung ( Figure 5B ). Subset ratio analysis further showed that cDC2 maturation in the LLN correlated with reduction in the cDC2:cDC1 ratio in the lung and with an increase in cDC2:cDC1 ratio in the LLN ( Figure 5C ), suggesting that cDC2 maturation correlates with the accumulation of cDC2 in the LLN, as was seen in the large cDC2 aggregations identified in Figure 4 . As another approach to assess the tissue derivation of LN DCs, we assessed expression of markers previously found to be associated with specific mucosal sites (CD103 for intestines [Jaensson et al., 2008; Watchmaker et al., 2014] , and CD1a for lung [Demedts et al., 2005] ) in the tissue and draining LNs. CD103 was expressed by both cDC1 (Sirp-a À ) and cDC2 (Sirp-a + ) subsets, with the highest level of expression in intestinal sites (particularly in the jejunum) compared to other sites, including lungs (Figures S5B and S5C) . Comparing CD103 expression by cDCs between tissues and LNs reveals CD103 upregulation by cDC2 in the intestines, but not in the lung ( Figure 5D, top) , and exclusively by HLA-DR hi mature cDC2s in intestinal draining MLN, but not in LLN or ILN ( Figure 5E , top). Conversely, CD1a was expressed by lung, but not intestinal, cDC2 ( Figure 5D , bottom), and exclusively by the mature cDC2 fraction in LLN, but not MLN or ILN ( Figure 5E , bottom). These results provide evidence that cDC2 has specifically migrated from the mucosal site to the draining node in a localized fashion. Together, our findings suggest that LN mature cDCs derive, at least in part, from cDCs maturing in the tissues and migrating to the draining LN.
cDC Subset Frequency in Tissues Is Differentially Affected by Age
Our results reveal a hierarchy of maturation and migratory phenotypes on both the subset and tissue levels, with cDC2 exhibiting higher frequencies of mature and migratory cells and the LLN containing the highest proportion of mature and migratory cDCs. To investigate whether these subset-and tissue-specific cDC properties are maintained or altered during human life, we analyzed cDC subset frequency in tissues obtained from organ donors aged 3 months to 93 years. By plotting cDC subset frequency as a function of age, we found that overall subset frequencies remained relatively constant throughout life in most tissues. However, the jejunum and appendix contained higher cDC1 frequencies in younger donors ( Figure 6A ). Comparing frequencies in donors stratified by age groupings into children (age 0-9 years) and adults (age 20-plus years) shows that the jejunum of children contained higher cDC1 frequencies but comparable cDC2 and CD14 + cell frequencies compared to adults (Figures 6B and 6C) . However, cDC1, cDC2, and CD14 + cell frequencies in the MLN, which drains the intestines,
were comparable between children and adults ( Figure 6C ; individualized cDC2:cDC1 ratios in Figure S6A ), indicating that differences in DC content in early life were largely confined to intestinal sites.
cDC2 Maturation Dynamics over Human Life
We also investigated the effect of aging on cDC maturation, as well as cDC2 predominance among mature cDCs. Results from individual donors aged 3 months to 93 years show higher frequencies of mature cDCs in the LLN compared to MLN in infants and younger adults, with more comparable frequencies of mature cDCs in LLN and MLN at older ages ( Figure 7A, top) . This trend of increased maturation in multiple LNs with age is Lung sections were taken from the lateral basal region for each donor. *p < 0.05, **p < 0.01, ***p < 0.001.
observed in compiled results plotting the maturation ratio in the LLN, MLN, and ILN as a function of age ( Figure 7A , bottom, Figure S6B) . However, the predominant cDC2 representation within the mature DC fraction in different LNs was maintained with age ( Figure 7B ). Thus, while our data show an overall stability in DC content over life, small shifts in cDC frequency ( Figure 6 ) and maturation ( Figure 7 ) may indicate subtle alterations in tissue surveillance during the course of human life.
DISCUSSION
Maturation and migration from peripheral tissues to draining LNs constitutes a central paradigm in DC biology, but our understanding of this process derives primarily from animal models. In this study, we analyzed cDC subset distribution, maturation, and localization in up to 14 different tissue sites from 78 organ donors to identify patterns of DC distribution and migration. We combined quantitative analysis of cDC subset composition and maturation in multiple sites within and between individual donors of all ages to assess human DC tissue surveillance in the body over the human lifespan. Our analyses revealed that cDC subset composition is a function of the specific tissue site, that mature cDCs are localized primarily to LNs with the LLN having the highest frequency of mature DCs, that cDC2 is the predominant subset with maturation and migration properties, and that tissue-specific signatures distinguish lung and intestinal DCs, which can be used to track their migration to draining LNs. These distribution, maturation, and migration features of cDC subsets are largely maintained from infancy through old age, with some site-specific variations. Our findings indicate that DC subset composition, maturation, and migration exhibit lifelong adapta- tion to the tissue site, providing new insights into human DC biology important for the design of DC-targeted therapies. A key challenge in human DC research is selecting appropriate markers to unambiguously identify DC subsets in different stages of maturation. CD141-the most widely used (and often eponymous) cDC1 marker-was originally identified in blood cDC1 (Dzionek et al., 2000) but was subsequently shown to also be expressed on tissue cDC2 and CD14 + cells (McGovern et al., 2014) . We identified CD13 as a consistent tissue cDC1 marker, and by combining CD141, CD13 (cDC1 markers), CD1c, Sirp-a (cDC2 markers), CD14, CD64 (CD14 + cell markers), HLA-DR, and CD40 (maturation markers), we were able to accurately identify and characterize both mature and immature tissue DC subsets. Thus, our analysis of multiple tissues from individual donors has enabled us to develop a versatile and reliable human DC panel. Because many of the human tissues examined here had not been previously studied and analysis of DCs in multiple mucosal and lymphoid tissues from single individuals has not been previously accomplished, it was important to initially ''map'' the monocytic or DC populations and subsets in each site. We focused our studies on analyzing cDC subset composition; cDCs were present in all sites at a lower frequency than the major CD14 + monocytic subset but were enriched in lymphoid tissues. While cDC2 were the more frequent cDC subset in human tissues, cDC1 frequencies were enhanced in LNs. Importantly, the consistent findings between diverse donors suggest that cDC subset composition in tissues is a function of the specific tissue site rather than of the individual. The frequencies and ratio of cDC2 and cDC1 further delineated specific tissue groupings into circulatory, lymphoid tissue, GALT, mucosal sites, and lung and lung-draining LNs, which were distinguished by higher cDC2 content than the other sites. These tissue groupings include higher cDC2:cDC1 ratios in mucosal sites that could reflect localized tissue surveillance. We used multiple overlapping analyses, including cell frequency, subset and maturation ratio, chemokine receptor and integrin expression, cell density and localization, and tissue-to-LN tracking using tissue-specific markers (CD1a and CD103) to investigate patterns of cDC migration. We found phenotypes associated with mature and migratory DCs in peripheral and mucosal-draining LNs, with mature HLA-DR hi cDCs also expressing the migration marker CCR7 ( LLN contained the highest fraction of mature cDCs in the majority of donors compared to the other LNs, including MLN, which drains the intestines, with spleen containing few mature cDCs, consistent with their lack of afferent lymphatics. Phenotypically mature cDCs have been identified in human lymph nodes (Desch et al., 2016; Haniffa et al., 2012; Segura et al., 2012) ; however, these previous studies examined fewer numbers and types of tissues and did not include mucosal tissues and their associated draining LNs, as done here.
Our results demonstrate tissue localization of DC surveillance in the body, with lung being a more dynamic site of DC maturation and migration compared to intestines. Using paired analysis of mucosal sites and their associated draining LNs, we were able to compare cDC subset maturation between sites, providing clues into the identity of migratory cDCs. Importantly, we identified a preferential expression of maturation and migration markers by cDC2 compared to cDC1 in tissues, which was more clearly delineated in tissue-draining LNs. While these results suggest that cDC2 have distinct functions as mucosal tissue sentinels, we did observe cDC1 with maturation and migratory phenotypes, albeit to a much lower extent compared to cDC2. It is possible that the specialized function of cDC2 suggested by our data is a distinguishing feature of human cDC subsets, as in mice, both cDC1 and cDC2 migrate from the lung to the draining LNs in response to respiratory infections (Worbs et al., 2016) . However, we cannot rule out that cDC1s also play important roles in tissue surveillance and migration to LNs during active infection or inflammatory conditions not encountered in the samples analyzed here. Moreover, cDC1 could undergo phenotypic changes during their migration that preclude detection by the markers used here. Nevertheless, our findings provide strong evidence for localized surveillance by human cDC2 between mucosal tissues and their associated draining LNs.
Our study on human DCs can be distinguished from previous reports in the scope and number of tissues and individuals examined and the acquisition of physiologically healthy tissues from organ donors, contrasting surgical explants from diseased tissues, which are typical sources for immunological studies. Our experimental approach and analyses has been specifically designed to assess how the donor population or donor state may impact our results. In our previous studies on T cell populations in these tissues, we found that variations in subset composition, activation state, and function were largely associated with the tissue rather than a specific feature of the donors, including cause of death or hospital length of stay, with some specific variations based on donor age (Thome et al., 2014; Thome et al., 2016a; Thome et al., 2016b) . In this study, we found that the LLN was the site for the highest frequency of mature and migratory-phenotype DCs, which could arise due to the higher inflammatory environment of the lung due to constant exposure or as a result of all donors being intubated. However, the predominance of mature cDC2 in the LLN was not strongly associated with the presence of ALI in the donors, suggesting that the role of cDC2 in mucosal tissue surveillance, maturation, and migration may be a feature of the tissue environment.
We show that the tissue distribution of cDC1 and cDC2, the extent of cDC maturation in different LNs, and the higher frequency of mature cDC2 in tissues and LNs are largely maintained throughout life in humans, with some variations at the extreme ends of life. For example, while cDC1 frequency is largely conserved in tissues with age, higher frequencies of cDC1 are found in the jejunum and appendix in infant and pediatric donors. We recently reported that the infant jejunum is a site for localization of early memory T cells and high frequencies of regulatory T cells (Tregs) (Thome et al., 2016a) . In mice, cDC1-mediated priming can promote generation of Tregs and oral tolerance (Esterhá zy et al., 2016) , and it would be interesting to determine if early intestinal DCs in human likewise promote a localized regulatory milieu. Moreover, while increased cDC2 maturation in the LLN compared to the MLN and other peripheral LNs is observed from infancy through old age (contrasting the defective cDC2 maturation observed in neonatal lung cDC2 in mice [Ruckwardt et al., 2014] ), we found increased cDC2 maturation in the MLN in older donors, suggesting an increase or broadening of cDC2 surveillance over life. Overall, the maintenance of tissue cDC subset distribution and function throughout life suggests a lifelong division of labor between cDC subsets that is essential to maintain immune health.
The emergence of mucosal vaccination approaches and cancer immunotherapy over the last few years has highlighted the need to better understand human DC biology. We present here a multi-dimensional study of cDC distribution and function over human life. Our findings reveal tissue-specific compartmentalization of adaptive immunity at the level of tissue surveillance by cDCs and could serve as a framework for harnessing the remarkable sensitivity, responsiveness, and migratory potential of human cDCs.
EXPERIMENTAL PROCEDURES
Acquisition of Tissue from Human Organ Donors Human tissues were obtained from deceased organ donors at the time of organ acquisition for clinical transplantation through an approved research protocol and MTA with LiveOnNY, the organ procurement organization for the New York metropolitan area. All donors were free of chronic disease and cancer and were negative for Hepatitis B and C and HIV. Tissues were collected after the donor organs were flushed with cold preservation solution and after the clinical procurement process was completed. The study does not qualify as ''human subjects'' research, as confirmed by the Columbia University IRB, as tissue samples were obtained from brain-dead (deceased) individuals. Demographic and clinical data were extracted from summaries prepared by LiveOnNY. Acute Lung Injury (ALI) (now referred to as mild ARDS) was calculated based on DonorNet records and defined using the Berlin criteria (ARDS Definition Task Force et al., 2012): acute lung changes developing over < 1 week, bilateral infiltrates on chest X-ray or CT (at least three lung lobes involved) not explained solely by atelectasis or nodules, hypoxemia defined by PaO2:FiO2 ratio < 300, and absence of left-sided heart failure.
Cell Isolation from Human Lymphoid and Non-lymphoid Tissues
Tissue samples were maintained in cold saline and brought to the laboratory within 2-4 hr of organ procurement. Intestinal sections were washed several times in cold PBS (Mediatech) and dried with paper towels; mucosal tissues were carefully inspected for the presence and removal of LN, then samples were processed using enzymatic and mechanical digestion resulting in high yields of live leukocytes, as described (Sathaliyawala et al., 2013) .
Flow Cytometry Analysis
Single-cell suspensions obtained as described above were blocked using Human TruStain FcX (Biolegend) and then stained with a 14-color antibody panel (see Table S2 for list) for 30 min on ice, with DAPI added 3 min before washing the samples in 2 mL FACS buffer. Cells were acquired on a 6-laser LSRII analytical flow cytometer (BD Biosciences). Control samples included unstained and single-fluorochrome-stained compensation beads (OneComp ebeads, eBioscience) for accurate compensation and subsequent data analysis, and fluorescence minus one (FMO) for CCR7, CD103, and CD40 expression on DCs. Flow cytometry data were analyzed using FlowJo software (Treestar).
Immunofluorescence Imaging
Fresh human LLN and MLN isolated from organ donors were fixed immediately in 1.0% paraformaldehyde and 0.1M L-Lysine (Sigma-Aldrich), added to PBS (pH7.4), incubated in 20% sucrose at 4 C, embedded in tissue-tek OCT compound (Sakura Finetek USA), and stored at À80 C. Thin 5-to 8-mm-thick sections were cut with Leica CM 1950 cryostat (Leica Microsystems GmbH). For staining, sections were permeabilized in PBS containing 0.1% Triton X-100 (Sigma-Aldrich) and 20% blocking reagent Blocking One (Nacalai tesque), incubated in blocking buffer (PBS + 20% blocking reagent; Blocking One), and incubated with unconjugated primary antibodies followed by fluorochrome-conjugated secondary antibodies in blocking buffer at room temperature, and then incubated with fluorochrome-conjugated antibodies at 4 C.
See Table S2 for a list of primary antibodies used for imaging. Secondary antibodies were conjugates of Alexa Fluor 555 and Alexa Fluor 647 (1:2000; Thermo Fisher Scientific). Samples were mounted on coverslips with Prolong Diamond Antifade Mountant (Life Technologies). Imaging was performed on a Leica DMI 6000 microscope (Leica Microsystems GmbH) with motorized z focus stage for fully automated image stitching. cDC2s were identified using the ''spots'' command in Imaris software (Bitplane), and nonspecific fluorescence signals were manually removed. The T cell zone area were defined using ImageJ software (National Institutes of Health).
Statistical Analysis and Data Visualization
Descriptive statistics (percent, mean, median, SEM) were calculated for each cell subset and tissue using GraphPad Prism (Graphpad Softfware). Significant differences in subset frequencies, ratios, gMFI, and density were assessed using a paired t test. Correlations were assessed using linear or curved regression lines. For ALI, statistical significance was assessed using a nonparametric Mann-Whitney U test.
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